SB-332235

Cat. No.:	HY-16981
CAS No.:	276702-15-9
Molecular Formula:	$C_{13}H_{10}Cl_3N_3O_4S$
Molecular Weight:	410.66
Target:	CXCR
Pathway:	GPCR/G Protein; Immunology/Inflammation
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description

SB-332235 is a potent, orally active nonpeptide CXCR2 antagonist, with an IC_{50} of 7.7 nM. SB-332235 displays 285-fold selectivity for CXCR2 over CXCR1. SB-332235 inhibits acute and chronic models of arthritis in the rabbit. SB-332235 inhibits viability of AML cells[1][2].

In Vitro

SB-332235 (1-100 μM; 48 hours) inhibits viability of AML cell lines[2].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay[2]

Cell Line:	AML cell
Concentration:	1, 10, 100 μM
Incubation Time:	48 hours
Result:	Led to a dose-dependent decrease in proliferation in all cell lines.

In Vivo

SB-332235 (25 mg/kg, p.o., b.i.d.) exhibits significantly reduced numbers of total leukocytes in synovial fluids from IL-8-injected knees[1].

SB-332235 (10-25 mg/kg; p.o.; twice a day for 14 days) inhibits chronic Ag-induced arthritis[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Adult female New Zealand White rabbits (chronic OVA-induced model of arthritis)[1]
Dosage:	10, 25 mg/kg
Administration:	P.o.; twice a day for 14 days
Result:	Day-15 synovial fluid leukocyte numbers in OVA-injected knees were significantly reduced in rabbits. The decrease in neutrophils, monocytes, and lymphocytes resulting from treatment with 25 mg/kg of the antagonist was accompanied by a significant reduction in synovial fluid PGE2, LTB4, LTC4, and IL-8 levels.

REFERENCES

[1]. Podolin PL, et al. A potent and selective nonpeptide antagonist of CXCR2 inhibits acute and chronic models of arthritis in the rabbit. J Immunol. 2002;169(11):6435-6444.

[2]. Schinke C, et al. IL8-CXCR2 pathway inhibition as a therapeutic strategy against MDS and AML stem cells [published correction appears in Blood. 2015 Jul 16;126(3):425. Barreryo, Laura [corrected to Barreyro, Laura]]. Blood. 2015;125(20):3144-3152.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA